Drug Price Trends for AMABELZ

Average Pharmacy Cost for AMABELZ

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
AMABELZ 0.5 MG-0.1 MG TABLET	68180-0829-71	0.59969	EACH	2025-04-23
AMABELZ 0.5 MG-0.1 MG TABLET	68180-0829-73	0.59969	EACH	2025-04-23
AMABELZ 1 MG-0.5 MG TABLET	68180-0830-71	0.68816	EACH	2025-04-23

Market Analysis and Price Projections for Amabelz

Last updated: February 20, 2026

What is Amabelz?

Amabelz (generic name: silver sulfadiazine) is a topical antimicrobial agent primarily used to prevent and treat infections in burn wounds. It has been in use for decades, with established FDA approval for burn care since the 1960s. The drug's current formulations are available in cream forms with varying strengths.

Current Market Position

Indications and Formulations

• Indications: Treatment of burn wound infections, prophylaxis of wound infections.
• Formulations: 1% silver sulfadiazine cream; some formulations include alternative delivery systems such as ointments or gels.

Market Size

The global burn care market was valued at approximately USD 1.2 billion in 2022. Silver sulfadiazine accounts for a significant share, estimated around USD 450 million, considering its historical prevalence and usage rates.

Competitive Landscape

• Key competitors include Bacitracin, Mupirocin, and other antimicrobial creams.
• Emerging products include advanced dressings infused with antimicrobial agents or nanotechnology-based delivery systems.
• Silver sulfadiazine faces competition from newer, potentially more effective or easier-to-apply agents, but remains a standard for many burn cases.

Market Drivers

• Increase in burn injuries globally, driven by industrial accidents, terrorism, and urbanization.
• Rising awareness of infection control measures.
• Expanding use in low- and middle-income countries where traditional burn care remains dominant.

Market Challenges

• Concerns over systemic toxicity and side effects such as leukopenia.
• Emergence of bacterial resistance.
• Development of alternative wound care products.

Regulatory Environment

• Approved and marketed in multiple countries including the US, EU, and emerging markets.
• Ongoing research on formulations with improved safety profiles.

Price Analysis

Current Pricing

Region	Average Price (USD) per 30g Tube	Notes
United States	$20 - $25	Retail price; wholesale prices are lower (~$12)
European Markets	€15 - €22	Equivalent to USD 16 - USD 23
Asia (India)	$8 - $12	Generic formulations dominate

Price Trends

• US prices have shown stability with slight increases (~2-3%) annually.
• European prices mirror inflation and regulatory costs.
• Developing countries see more significant price variability driven by local manufacturing and import tariffs.

Projected Price Trajectory (Next 5 Years)

Region	Expected Price Range (USD)	Key Factors
United States	$21 - $27	Inflation, manufacturing costs, regulatory review
Europe	€16 - €24	Regulatory updates, generic competition, inflation
Asia	$9 - $14	Market expansion, local manufacturing, competition

Assumptions for Projections

• Continued demand due to burn incident rates.
• No sudden regulatory changes significantly affecting pricing.
• Entry of new generic competitors could pressure prices downward.
• Development of improved formulations may lead to premium pricing.

Potential Impact of New Developments

Innovative Formulations

• Liposomal or nanotech-based silver sulfadiazine could command premium pricing.
• Sustained-release topical formulations may extend product life cycles.

Regulatory Milestones

• New approvals for combination products for burn care.
• Price adjustments following regulatory changes or biosimilar developments.

Summary

Amabelz markets approximately USD 450 million globally, with US prices around USD 20-25 per 30g tube. Market stability persists, but emerging competition and innovations could influence future price trajectories. Regional variability remains substantial, with lower prices in Asia driven by manufacturing and generic competition.

Key Takeaways

• Amabelz holds a significant share in burn wound management, driven by its longstanding approval status and clinical efficacy.
• Price stability will likely continue in developed markets, yet prices in emerging economies may see moderate increases or reductions based on local dynamics.
• Innovation and regulatory changes are potential catalysts for price adjustments over the next five years.
• Competition from newer or alternative treatments could exert downward pressure on prices, especially in mature markets.
• Market growth hinges on the prevalence of burns and infection control practices, particularly in low- and middle-income countries.

FAQs

1. How does Amabelz compare in cost to alternative burn treatments?
Amabelz is generally more expensive than simpler antimicrobial ointments like bacitracin but cost-effective given its efficacy and standard use in severe burns.

2. What factors could influence Amabelz's market share?
Emergence of new antimicrobial dressings, regulatory changes, rising resistance, and innovations in burn treatment.

3. Are there upcoming regulatory changes likely to impact prices?
Possible approval of novel formulations or biosimilars could influence pricing, although no immediate regulatory shifts are forecasted.

4. Which regions are expected to see the fastest market growth?
Asia and Africa, due to increasing burn incidence and expanding healthcare infrastructure.

5. What is the potential for generic versions to reduce prices?
High, especially in markets with established manufacturing capacity, leading to increased competition and downward pressure on prices.

---

References

[1] MarketsandMarkets. (2022). Burn Care Market by Product, Application, End User, and Region.
[2] Allied Market Research. (2021). Silver Sulfadiazine Market Analysis.
[3] U.S. Food and Drug Administration (FDA). (1968). Approval of Silver Sulfadiazine.
[4] European Medicines Agency (EMA). (2022). Summary of Product Characteristics for Silver Sulfadiazine.